Study of a new anemia pill for people on dialysis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new oral medication (QLG1218, also called daprodustat) to treat anemia in people with chronic kidney disease who are on hemodialysis. It is comparing the new drug to the usual injected ESA medicines to see if it works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your weight is between 99 and 220 pounds (45 to 100 kg).
- You have been on hemodialysis (or hemodiafiltration) three times a week for at least 12 weeks.
- Your hemoglobin (Hb) levels are between 95 and 120 g/L (with only a small difference between two recent tests).
- Your iron levels are adequate (TSAT >20% and ferritin >100).
- You have been using the same type of ESA (erythropoiesis-stimulating agent) for the last 10 weeks, at a specific dose range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This study looks at how well Daprodustat works for anemia in people with chronic kidney disease, including those on dialysis or after a kidney transplant. It collects real-world data to help doctors manage this condition.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
This trial tests whether taking an oral pill three times a week (vadadustat) works as well as injections (Epogen) to treat anemia—low red blood cells—in people on dialysis. If it works, a pill might be easier and more convenient than injections.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
Hear when a new Anaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.